AbbVie Inc

ISIN US00287Y1091 Symbol ABBV Industry Drug Manufacturers-General Sector Healthcare
AbbVie Price
115.5USD 0.73%
1y Low: 67.8
1y High: 113.4
1y Low: 67.8
1y High: 113.4
AbbVie Analyst Rating
Strong Buy
Strong Sell
Market Cap
183.3 B USD
Dividend Yield
Performance 1y
2.91 %

AbbVie Stock Chart

AbbVie Dividend Chart

AbbVie Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022 0 0 USD 0.0 %
2021 3 3.90 USD 0.0 %
2020 4 4.72 USD 4.6 %
2019 4 4.28 USD 5.1 %
2018 4 3.59 USD 4.3 %
2017 4 2.56 USD 3.0 %
2016 4 2.28 USD 4.4 %
2015 4 2.02 USD 4.3 %
2014 4 1.66 USD 3.2 %
2013 4 1.60 USD 4.0 %

AbbVie Performance

1 Week
1 Month
6 Months
Year to Date
1 Year
2.91 %
5 Years
123.6 %

AbbVie Revenue, EBIT, and Income

AbbVie Margins

AbbVie Shares Outstanding

Useful Links

Search Twitter: $ABBV, #ABBV

AbbVie Company Info

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.

AbbVie Price to Earnings Ratio (PE Ratio): 38.2

The current Price to Earnings Ratio of AbbVie is 38.2.
The PE Ratio is calcluated by dividing the current AbbVie share price (115.5 USD) by the earnings per share (2.7).

AbbVie Dividend Yield: 4.7%

The current Dividend Yield of AbbVie is 4.7%.

AbbVie Market Cap: 183.3 B USD

The current market cap of AbbVie is 183.3 B USD.

AbbVie Stock Price: 115.5 USD

The current stock price of AbbVie is 115.5 USD.

AbbVie ISIN: US00287Y1091

The ISIN (International Securities Identification Number) of AbbVie is US00287Y1091.

AbbVie Ticker Symbol: ABBV

The ticker symbol of AbbVie is ABBV.

AbbVie Address

The address of the AbbVie HQ is 1 North Waukegan Road, 60064 North Chicago, IL, USA.